Skip to main content

06.12.2024 | Research

Bacteremic nosocomial pneumonia caused by Gram-negative bacilli: results from the nationwide ALARICO study in Italy

verfasst von: Giusy Tiseo, Valentina Galfo, Sergio Carbonara, Andrea Marino, Giovanni Di Caprio, Anna Carretta, Alessandra Mularoni, Michele Fabiano Mariani, Alberto Enrico Maraolo, Riccardo Scotto, Lidia Dalfino, Lorenzo Corbo, Margherita Macera, Alice Annalisa Medaglia, Maria Luca d’Errico, Claudia Gioè, Christian Sgroi, Rosa Fontana Del Vecchio, Giancarlo Ceccarelli, Antonio Albanese, Calogero Buscemi, Simona Talamanca, Giuseppe Foti, Giulio De Stefano, Antonina Franco, Carmelo Iacobello, Salvatore Corrao, Domenico Morana, Filippo Pieralli, Ivan Gentile, Teresa Santantonio, Antonio Cascio, Nicola Coppola, Bruno Cacopardo, Mario Venditti, Francesco Menichetti, Marco Falcone, ALARICO Network

Erschienen in: Infection

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe the clinical characteristics and outcomes of patients with nosocomial pneumonia (NP) caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) and to compare them to patients with NP caused by carbapenem-susceptible (CS)-GNB.

Methods

Prospective observational multicenter study including patients with bacteremic NP caused by GNB from the ALARICO Network (June 2018-January 2020). The primary outcome measure was 30-day mortality. A Cox regression analysis was performed to identify factors independently associated with 30-day mortality. Hazard ratio (HR) and 95% confidence intervals (CI) were calculated.

Results

Overall, 167 patients with GNB NP were included: 101 with bacteremic NP caused by CR-GNB (n = 39 by KPC-producing Klebsiella pneumoniae, n = 29 by carbapenem-resistant Acinetobacter baumannii, n = 28 by carbapenem-resistant Pseudomonas aeruginosa, n = 5 by MBL-producing Klebsiella pneumoniae) and 66 cases of bacteremic CS-GNB NP. Thirty-day mortality rate was higher in patients with NP caused by CR-GNB compared to those with NPcaused by CS-GNB (46.5% vs 30.3%, p = 0.036). On multivariable analysis, age (HR 1.044, 95% CI 1.021–1.067, p < 0.001), hematological malignancy (HR 4.307, 95% CI 1.924–9.643, p < 0.001) and septic shock (HR 3.668, 95% CI 2.001–6.724, p < 0.001) were factors independently associated with 30-day mortality, while the receipt of adequate antibiotic therapy within 24 h from infection onset (HR 0.495, 95% CI 0.252–0.969, p = 0.04) was a protective factor. Carbapenem resistance was not associated with increased risk of mortality (HR 1.075, 95% CI 0.539–2.142, p = 0.837).

Conclusions

Patients with bacteremic NP caused by CR-GNB have high mortality rate. Strategies to reduce the time from infection to the administration of adequate antibiotic therapy should be implemented in patients with NP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med. 2018;379:1732–44.CrossRefPubMedPubMedCentral Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med. 2018;379:1732–44.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–9.CrossRefPubMed Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–9.CrossRefPubMed
3.
Zurück zum Zitat Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19:219.CrossRefPubMedPubMedCentral Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19:219.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis. 2011;15:e545–50.CrossRefPubMed Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int J Infect Dis. 2011;15:e545–50.CrossRefPubMed
5.
Zurück zum Zitat Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078–84.CrossRefPubMed Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078–84.CrossRefPubMed
6.
Zurück zum Zitat Jones BE, Sarvet AL, Ying J, Jin R, Nevers MR, Stern SE, et al. Incidence and Outcomes of non-ventilator-associated hospital-acquired pneumonia in 284 US hospitals using electronic surveillance criteria. JAMA Netw Open. 2023;6: e2314185.CrossRefPubMedPubMedCentral Jones BE, Sarvet AL, Ying J, Jin R, Nevers MR, Stern SE, et al. Incidence and Outcomes of non-ventilator-associated hospital-acquired pneumonia in 284 US hospitals using electronic surveillance criteria. JAMA Netw Open. 2023;6: e2314185.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Micek ST, Chew B, Hampton N, Kollef MH. A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest. 2016;150:1008–14.CrossRefPubMed Micek ST, Chew B, Hampton N, Kollef MH. A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest. 2016;150:1008–14.CrossRefPubMed
8.
Zurück zum Zitat Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med. 2011;39:2736–42.CrossRefPubMed Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med. 2011;39:2736–42.CrossRefPubMed
9.
Zurück zum Zitat Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Diaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020;24:383.CrossRefPubMedPubMedCentral Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Diaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020;24:383.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Falcone M, Giordano C, Leonildi A, Galfo V, Lepore A, Suardi LR, Riccardi N, Barnini S, Tiseo G. Clinical features and outcomes of infections caused by metallo-β-lactamase–producing enterobacterales: a 3-year prospective study from an endemic area. Clin Infect Dis. 2023;78(5):1111–9. https://doi.org/10.1093/cid/ciad725.CrossRef Falcone M, Giordano C, Leonildi A, Galfo V, Lepore A, Suardi LR, Riccardi N, Barnini S, Tiseo G. Clinical features and outcomes of infections caused by metallo-β-lactamase–producing enterobacterales: a 3-year prospective study from an endemic area. Clin Infect Dis. 2023;78(5):1111–9. https://​doi.​org/​10.​1093/​cid/​ciad725.CrossRef
11.
Zurück zum Zitat Willems RPJ, van Dijk K, Vehreschild MJGT, Biehl LM, Ket JCF, Remmelzwaal S, et al. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis. 2023;23(6):719–31.CrossRefPubMed Willems RPJ, van Dijk K, Vehreschild MJGT, Biehl LM, Ket JCF, Remmelzwaal S, et al. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis. 2023;23(6):719–31.CrossRefPubMed
12.
Zurück zum Zitat Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef
13.
Zurück zum Zitat Falcone M, Giordano C, Barnini S, Tiseo G, Leonildi A, Malacarne P, et al. Extremely drug-resistant NDM-9-producing ST147 Klebsiella pneumoniae causing infections in Italy, May 2020. Euro Surveill. 2020;25:2001779.CrossRefPubMedPubMedCentral Falcone M, Giordano C, Barnini S, Tiseo G, Leonildi A, Malacarne P, et al. Extremely drug-resistant NDM-9-producing ST147 Klebsiella pneumoniae causing infections in Italy, May 2020. Euro Surveill. 2020;25:2001779.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66: e0214221.CrossRefPubMed Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66: e0214221.CrossRefPubMed
15.
Zurück zum Zitat Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A Novel Algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155:1119–30.CrossRefPubMed Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A Novel Algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155:1119–30.CrossRefPubMed
16.
Zurück zum Zitat Chen CY, Yang KY, Peng CK, Sheu CC, Chan MC, Feng JY, et al. Clinical outcome of nosocomial pneumonia caused by carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study. Sci Rep. 2022;12:7501.CrossRefPubMedPubMedCentral Chen CY, Yang KY, Peng CK, Sheu CC, Chan MC, Feng JY, et al. Clinical outcome of nosocomial pneumonia caused by carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study. Sci Rep. 2022;12:7501.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24:29.CrossRefPubMedPubMedCentral Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24:29.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22:444–50.CrossRefPubMed Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22:444–50.CrossRefPubMed
19.
Zurück zum Zitat Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis. 2023;76:2059–69.CrossRefPubMed Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis. 2023;76:2059–69.CrossRefPubMed
20.
Zurück zum Zitat Martin-Loeches I, Reyes LF, Nseir S, Ranzani O, Povoa P, Diaz E, et al. European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI. Intensive Care Med. 2023;49:1212–22.CrossRefPubMedPubMedCentral Martin-Loeches I, Reyes LF, Nseir S, Ranzani O, Povoa P, Diaz E, et al. European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI. Intensive Care Med. 2023;49:1212–22.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Executive summary: surviving sepsis campaign: international guidelines for the management of sepsis and septic shock. Crit Care Med. 2021;49:1974–82.CrossRefPubMed Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Executive summary: surviving sepsis campaign: international guidelines for the management of sepsis and septic shock. Crit Care Med. 2021;49:1974–82.CrossRefPubMed
22.
Zurück zum Zitat Falcone M, Tiseo G, Galfo V, Giordano C, Leonildi A, Marciano E, et al. Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). Clin Microbiol Infect. 2022;28:298.e1-298.e7.CrossRefPubMed Falcone M, Tiseo G, Galfo V, Giordano C, Leonildi A, Marciano E, et al. Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). Clin Microbiol Infect. 2022;28:298.e1-298.e7.CrossRefPubMed
23.
Zurück zum Zitat Beuving J, Wolffs PF, Hansen WL, Stobberingh EE, Bruggeman CA, Kessels A, et al. Impact of same-day antibiotic susceptibility testing on time to appropriate antibiotic treatment of patients with bacteraemia: a randomised controlled trial. Eur J Clin Microbiol Infect Dis. 2015;34:831–8.CrossRefPubMed Beuving J, Wolffs PF, Hansen WL, Stobberingh EE, Bruggeman CA, Kessels A, et al. Impact of same-day antibiotic susceptibility testing on time to appropriate antibiotic treatment of patients with bacteraemia: a randomised controlled trial. Eur J Clin Microbiol Infect Dis. 2015;34:831–8.CrossRefPubMed
24.
Zurück zum Zitat Kim JH, Kim I, Kang CK, Jun KI, Yoo SH, Chun JY, et al. Enhanced antimicrobial stewardship based on rapid phenotypic antimicrobial susceptibility testing for bacteraemia in patients with haematological malignancies: a randomized controlled trial. Clin Microbiol Infect. 2021;27:69–75.CrossRefPubMed Kim JH, Kim I, Kang CK, Jun KI, Yoo SH, Chun JY, et al. Enhanced antimicrobial stewardship based on rapid phenotypic antimicrobial susceptibility testing for bacteraemia in patients with haematological malignancies: a randomized controlled trial. Clin Microbiol Infect. 2021;27:69–75.CrossRefPubMed
25.
Zurück zum Zitat Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73:1664–76.CrossRefPubMed Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73:1664–76.CrossRefPubMed
26.
Zurück zum Zitat Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018;62:e02497-e2517.CrossRefPubMedPubMedCentral Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018;62:e02497-e2517.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Tiseo G, Galfo V, Riccardi N, Suardi LR, Pogliaghi M, Giordano C, et al. Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2024 Feb 20. Epub ahead of print Tiseo G, Galfo V, Riccardi N, Suardi LR, Pogliaghi M, Giordano C, et al. Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2024 Feb 20. Epub ahead of print
Metadaten
Titel
Bacteremic nosocomial pneumonia caused by Gram-negative bacilli: results from the nationwide ALARICO study in Italy
verfasst von
Giusy Tiseo
Valentina Galfo
Sergio Carbonara
Andrea Marino
Giovanni Di Caprio
Anna Carretta
Alessandra Mularoni
Michele Fabiano Mariani
Alberto Enrico Maraolo
Riccardo Scotto
Lidia Dalfino
Lorenzo Corbo
Margherita Macera
Alice Annalisa Medaglia
Maria Luca d’Errico
Claudia Gioè
Christian Sgroi
Rosa Fontana Del Vecchio
Giancarlo Ceccarelli
Antonio Albanese
Calogero Buscemi
Simona Talamanca
Giuseppe Foti
Giulio De Stefano
Antonina Franco
Carmelo Iacobello
Salvatore Corrao
Domenico Morana
Filippo Pieralli
Ivan Gentile
Teresa Santantonio
Antonio Cascio
Nicola Coppola
Bruno Cacopardo
Mario Venditti
Francesco Menichetti
Marco Falcone
ALARICO Network
Publikationsdatum
06.12.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02423-6

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.